BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

19 articles for Y Ran

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.EBI
Genentech
Rational design, synthesis, and pharmacological properties of pyranochalcone derivatives as potent anti-inflammatory agents.EBI
Sichuan University
Design, synthesis, and biological evaluation of novel N-Benzyl piperidine derivatives as potent HDAC/AChE inhibitors for Alzheimer's disease.EBI
Shandong University
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.EBI
Genentech
Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer.EBI
Genentech
Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer.EBI
Genentech
Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha.EBI
Genentech
Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.EBI
Shandong University
Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors.EBI
Genentech
Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity.EBI
Genentech
Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases.EBI
Shandong University
Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.EBI
Array Biopharma
Pyrazolopyridine inhibitors of B-Raf(V600E). Part 3: an increase in aqueous solubility via the disruption of crystal packing.EBI
Array Biopharma
GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP).EBI
Genentech
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.EBI
Genentech
Benzimidazol-2-amines as MIDH1 inhibitorsBDB
Bayer Pharma Aktiengesellschaft
Pharmacological characterization of the constitutively activated state of the serotonin 5-HT2C receptor.BDB
Albany Medical College
Time-dependent inactivation of aromatase by 6-alkylandrosta-1,4-diene-3,17-diones. Effects of length and configuration of 6-alkyl group.BDB
Tohoku College of Pharmacy
N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.BDB
Glaxosmithkline